Mymetics Announces New Study to Predict Efficacy of Second- Generation COP Allergy Immunotherpy with Virosomes

October 17, 2019 6:00 AM

- The second-generation Allergen Immunotherapy based on Anergis Continous Overlapping Peptides (COP) linked to Mymetics Virosomes will be tested by Stallergenes Greer using its therapeutic model of birch allergy - Results of the study are expected in Q1 2020 EPALINGES, SWITZERLAND / ACCESSWIRE / October 17, 2019 / Mymetics Corporation (OTCQB:MYMX), a pioneer and leader in the research and development of virosome-based vaccines and...

Read more

Xenetic Biosciences, Inc. to Present at BIO Investor Forum

October 16, 2019 8:05 AM

Presentation with Live Audio Webcast on Wednesday, October 23rd at 2:45 PM PT FRAMINGHAM, MA / ACCESSWIRE / October 16, 2019 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART, a personalized chimeric antigen receptor T cell ("CAR T") platform technology engineered to target patient-specific tumor neoantigens, announced today that Jeffrey...

Read more

Hancock Jaffe to Present at the Inaugural MicroCap Rodeo Investor Conference on October 16, 2019

October 14, 2019 12:15 PM

IRVINE, CA / ACCESSWIRE / October 14, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, has been invited to present at the inaugural MicroCap Rodeo Investor Conference on October 16, 2019 in Austin. The MicroCap Rodeo Investor Conference is being held October 15-16, 2019 at the Hilton Austin in Austin, Texas. Hancock Jaffe CEO Rob Berman is scheduled...

Read more

Dyadic to Attend Three Upcoming Investor Conferences in October

October 10, 2019 8:30 AM

JUPITER, FL / ACCESSWIRE / October 10, 2019 / Dyadic International, Inc. (the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its President and Chief Executive...

Read more

Wellmetrix and DSM Announce Research Partnership to Assess Diagnostic Platform for Personalized Nutrition

October 8, 2019 11:05 AM

KEEGO HARBOR, MI / ACCESSWIRE / October 8, 2019 / Personal health testing developer Wellmetrix and Royal DSM, a purpose-led, global science-based company active in Nutrition, Health and Sustainable Living, have announced a research partnership to explore the use of Wellmetrix's diagnostic platform to perform non-invasive and point-of-need measurements of key health biomarkers as part of a nutrition intervention using combinations of...

Read more

Xenetic Biosciences, Inc. Provides Business Outlook

October 8, 2019 8:30 AM

Recent completion of acquisition of innovative CAR T technology platform (XCART) has the potential to drive significant value for shareholders Management working with KOLs and subject matter experts to formalize XCART development plan Completion of recent financing expected to fund operations through key development milestones Proprietary technology, PolyXen™, expected to generate royalties as early as Q4 2019 FRAMINGHAM,...

Read more

Angle PLC Annouces Notice of AGM

October 8, 2019 2:00 AM

Notice of AGM and Posting of Annual Report and Accounts GUILDFORD, SURREY / ACCESSWIRE / October 8, 2019 / ANGLE plc (AIM:AGL) (OTCQX:ANPCY), a world-leading liquid biopsy company, announces that its AGM will be held at 2:00 pm on Wednesday 30 October 2019 at ANGLE plc, 10 Nugent Road, Surrey Research Park, Guildford, GU2 7AF. The Annual Report and Accounts for the year ended 30 April 2019, were posted to shareholders on 7 October 2019,...

Read more

Late-Stage Data from Abicipar in Age-Related Macular Degeneration to be Showcased at American Academy of Ophthalmology (AAO) Annual Meeting

October 4, 2019 1:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / October 4, 2019 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*, today announced that its partner Allergan plc, (NYSE:AGN), a leading global pharmaceutical company with a more than 70-year heritage in ophthalmology, will present new data from investigational Abicipar at the Annual Meeting of the American...

Read more

American CryoStem Expands Investigator Team with Sub-Investigators for Post Concussive Syndrome IND

October 3, 2019 6:00 AM

The Company and the Principal Investigator announce the addition of sub-investigators to the clinical trial team with extensive experience assessing and treating athletes and military personnel suffering from concussion injury, traumatic brain injury and Post Concussion Syndrome EATONTOWN, NJ / ACCESSWIRE / October 3, 2019 / American CryoStem Corporation (OTC PINK:CRYO) a leading strategic developer, marketer and global licensor of patented...

Read more

Molecular Partners Announces First Patient Dosed in Phase 1 Trial of MP0310, a Novel Tumor-Localized Immunotherapy

October 3, 2019 1:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / October 3, 2019 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*, today announced that the first patient has been enrolled and dosed in a Phase 1 first-in-human study of MP0310 as a single agent in patients with advanced solid tumors. The trial, entitled MP0310-CP101, will evaluate the optimal dose range of...

Read more

Vitro Biopharma 3rd Quarter ended July 31st 2019 Financial Results of Operations

September 26, 2019 12:00 PM

GOLDEN, CO / ACCESSWIRE / September 26, 2019 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced its 3rd quarter ended September 24th 2019 financial results of operations. Vitro Diagnostics Inc. ("Vitro Biopharma") is pleased to announce a record 3rd quarter in Stem Cell Revenues. Vitro Biopharma recorded 3rd quarter revenues of $225,191 vs $141,783 an increase of 59% over the same comparative quarter last year....

Read more

Pieris Pharmaceuticals and AstraZeneca Present Multiple Ascending Dose Phase 1b Data for Inhaled IL4-Rα Antagonist AZD1402/PRS-060 at the 2019 European Respiratory Society International Congress

September 26, 2019 9:35 AM

BOSTON, MA / ACCESSWIRE / September 26, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced the presentation on October 1, 2019, of interim data from its placebo-controlled multiple ascending dose phase 1b study for AZD1402/PRS-060, an inhaled...

Read more

Hancock Jaffe to Host Virtual Roadshow Webinar on Thursday, October 3, 2019 at 4:30 p.m. Eastern Time

September 26, 2019 8:31 AM

IRVINE, CA / ACCESSWIRE / September 26, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, will host a virtual roadshow webinar on October 3, 2019 at 4:30 p.m. Eastern time. Robert Berman, Chief Executive Officer and Dr. Marc H. Glickman, Chief Medical Officer, will present an overview of the company's product pipeline, review of interim data and a...

Read more

Cofactor Genomics Expands Leadership Team and Opens New Boston Predictive Immune Modeling Center

September 26, 2019 7:00 AM

BOSTON, MA / ACCESSWIRE / September 26, 2019 / Today Cofactor Genomics announced that it has expanded the leadership team with the promotion of Natalie LaFranzo, PhD to Vice President of Market Development. Dr. LaFranzo's amplified leadership role includes clinical collaboration management, corporate partnerships, and strategic marketing. Dr. LaFranzo has been with Cofactor most recently for three years, with previous roles in product...

Read more

ReShape Lifesciences Enters into Early Warrant Exercise Transaction and Receives an Additional $7.65 Million in Proceeds

September 23, 2019 4:55 PM

SAN CLEMENTE, CA / ACCESSWIRE / September 23, 2019 / ReShape Lifesciences Inc. (OTCQB:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today entered into an early warrant exercise transaction with the holders of 400,000,000 Series B Warrants issued in ReShape's June 2019 private placement pursuant to a warrant exercise agreement. The early exercise of the warrants resulted in approximately...

Read more

DECN Retains Counsel To File For Two Patents Covering GenUltimate TBG Test Strip And System, Consents To The Publication A White Paper By A Biotech Industry Luminary

September 19, 2019 8:55 AM

3RD PARTY TESTING AND ANALYSIS OF COMPANY'S GENULTIMATE TBG REVEAL NEVER BEFORE SEEN PRECISION AND ACCURACY AT LEVELS 60% BETTER THAN FDA AND ISO PUBLISHED STANDARDS LOS ANGELES, CA / ACCESSWIRE / September 19, 2019 / Decision Diagnostics Corp. (OTC PINK:DECN) is a 17-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and...

Read more

American CryoStem Announces: FDA Accepted its Investigational New Drug Application for Post Concussion Syndrome

September 18, 2019 6:00 AM

ATCell™ Expanded Autologous, Adipose-Derived Mesenchymal Stem Cells Deployed via Intravenous Infusion for the Treatment of Post Concussion Syndrome (PCS) in Retired Military and Athletes EATONTOWN, NJ / ACCESSWIRE / September 18, 2019 / American CryoStem Corporation (OTC PINK:CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products and technologies for the Regenerative and...

Read more

Hancock Jaffe Appoints Global Healthcare Executive Matthew Jenusaitis and Financial and Medical Reimbursement Expert Robert Gray to its Board of Directors

September 16, 2019 8:31 AM

Experienced Medical Device and Reimbursement Executives Added to Board Ahead of Key Product Milestones and Pre-FDA Meetings IRVINE, CA / ACCESSWIRE / September 16, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, has appointed global healthcare executive Mr. Matthew Jenusaitis and reimbursement and financial expert Mr. Robert Gray to its board of...

Read more

DECN Launches Premier Versions Of Its Successful Genultimate Test Strip, Completes Media Commercial Set To Debut In National Media Markets

September 11, 2019 8:55 AM

LOS ANGELES, CA / ACCESSWIRE / September 11, 2019 / Decision Diagnostics Corp. (OTC PINK:DECN) is a 17-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the GenSure! ("Feather") diabetes test strip for International...

Read more

American CryoStem Engages BioSolutions Clinical Research Center, LLC. and Principal Investigator for Chronic Concussive Syndrome IND

September 11, 2019 6:00 AM

EATONTOWN, NJ / ACCESSWIRE / September 11, 2019 / American CryoStem Corporation (OTC PINK:CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products and technologies for the Regenerative and Personalized Medicine industries, today announced that it has contracted with BioSolutions Clinical Research Center, LLC. (“BioSolutions”) to conduct a clinical study (“Study”) of ATCELL™...

Read more